<DOC>
	<DOCNO>NCT00489697</DOCNO>
	<brief_summary>Bevacizumab , anti-angiogenic agent , plus fluorouracil base chemotherapy consider new standard treatment metastatic colorectal cancer . Contrast-enhanced ultrasound gas-encapsulated microbubbles use assess tumour vascularity , particularly hepatic metastasis , may become useful tool monitoring anti-angiogenic therapy . The aim prospective , multicenter , non-randomized study evaluate usefulness hepatic contrast-enhanced ultrasound predict response bevacizumab base chemotherapy patient metastatic colorectal cancer . The primary objective study compare functional vascular change relate bevacizumab base chemotherapy evaluate hepatic contrast-enhanced ultrasound classic RECIST criterion . The secondary objective characterization pharmacokinetic bevacizumab , explore pharmacodynamic effect bevacizumab functional vascular change hepatic metastasis evaluate hepatic contrast-enhanced ultrasound analyze possible relationship treatment efficacy toxicity constitutional gene polymorphism link bevacizumab .</brief_summary>
	<brief_title>Evaluation Contrast-enhanced Ultrasound Imaging Early Estimate Bevacizumab Effect Colorectal Cancer Liver Metastases</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Histologically confirm colorectal tumor first line treatment bevacizumab base chemotherapy Target hepatic metastasis size low 5 cm high 5 mm detect conventional ultrasonography CT MRI Life expectancy &gt; 2 month OMS status = &lt; 2 Major surgery , open biopsy , significant traumatic injury within 28 day prior Day 0 inform consent sign target hepatic lesion detect conventional ultrasonography Prior bevacizumab treatment Prior chemotherapy treatment advance disease Clinically significant cardiac disease ( e.g . myocardial infarction stroke within 12 month , unstable angina , New York Heart Association ( NYHA ) Grade II great congestive heart failure well control medication , endocarditis prosthetic valve ) contraindication sulphur hexafluoride administration Blood pressure &gt; = 180/110 mmHg Daily chronic treatment aspirin AINS Anticipation need major surgical procedure within 7 day prior day 0 Urine protein &gt; 1g/24 Hours Any contraindication enhance bevacizumab treatment Serious , uncontrolled , concurrent infection ( ) illness ( e ) pregnant lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>hepatic metastasis</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>anti-angiogenic agent</keyword>
	<keyword>chemotherapy regimen</keyword>
	<keyword>tumor vascularity</keyword>
	<keyword>Contrast-enhanced ultrasound</keyword>
</DOC>